CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme (1,2). CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine (3,4). Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme (4). Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II (5). The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus (5). CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets (1,3). CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke (6).
Key Feature
Clonality
Polyclonal
Isotype
IgG
Host Species
Rabbit
Tested Applications
WBIPIFELISA
recommended for detection of CD39 of mouse, rat and human origin by WB, IP, IF and ELISA
Species Reactivity
HumanMouseRat
Concentration
1mg/ml
Purification
Affinity purified
Target Information
Alternative Names
epitope corresponding to amino acids 256-340 mapping within an internal region of CD39 of human origin
Tissue Specificity
epitope corresponding to amino acids 256-340 mapping within an internal region of CD39 of human origin